Literature DB >> 35238782

Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting.

Zeynep Melekoglu Ellik1, Ilkay S Idilman2, Aysun Kartal1, Yasemin Balaban3, Atilla H Elhan4, Musturay Karcaaltincaba2, Hasan Ozkan1, Ramazan Idilman1.   

Abstract

BACKGROUND: Liver graft fibrosis affects long-term graft and patient survival in liver transplant recipients. Transient elastography and magnetic resonance elastography are widely used for the assessment of liver fibrosis in routine clinical practice, but are limited in liver transplant settings. The aims of the present study were to evaluate the accuracy of magnetic resonance elastography and transient elastograph in the assessment of liver fibrosis in liver transplant recipients, and to determine the recurrence rates of post-transplant hepatic steatosis and liver fibrosis.
METHODS: A total of 126 consecutive liver transplant recipients were included. Magnetic resonance elastography and transient elastography were performed for to measure liver stiffness.
RESULTS: The most common cause of liver transplantation was hepatitis B virus-induced cirrhosis (50%). The mean liver stiffness value with transient elastography was 6.1 ± 3.0 kPa, and the mean magnetic resonance elastography value was 2.7 ± 1.0 kPa. A significant positive correlation was found between magnetic resonance elastography and transient elastography in terms of liver stiffness measurement (r = 0.61, P < .001). Obesity and the underlying etiology of liver diseases did not have any significant negative effect on magnetic resonance elastography and transient elastography measurements. During the follow-up, the post-transplant recurrence rates of hepatic steatosis and hepatic fibrosis were 26% and 37%, respectively. The recurrence rates of post-transplant hepatic steatosis and liver fibrosis were slightly higher in recipients with non-alcoholic fatty liver disease-related cirrhosis than those with viral hepatitisrelated etiologies (44% vs 27%, P = .43; 44% vs 30%, P = .45, respectively).
CONCLUSION: Magnetic resonance elastography and transient elastography are accurate in assessing liver fibrosis in the liver transplant setting. Obesity and the underlying etiology of primary liver disease do not influence the measurements.

Entities:  

Mesh:

Year:  2022        PMID: 35238782      PMCID: PMC9128353          DOI: 10.5152/tjg.2022.21705

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  38 in total

1.  Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

Authors:  Leon A Adams; Jacob George; Elisabetta Bugianesi; Enrico Rossi; W Bastiaan De Boer; David van der Poorten; Helena L I Ching; Max Bulsara; Gary P Jeffrey
Journal:  J Gastroenterol Hepatol       Date:  2011-10       Impact factor: 4.029

Review 2.  Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis.

Authors:  Siddharth Singh; Sudhakar K Venkatesh; Rohit Loomba; Zhen Wang; Claude Sirlin; Jun Chen; Meng Yin; Frank H Miller; Russell N Low; Tarek Hassanein; Edmund M Godfrey; Patrick Asbach; Mohammad Hassan Murad; David J Lomas; Jayant A Talwalkar; Richard L Ehman
Journal:  Eur Radiol       Date:  2015-08-28       Impact factor: 5.315

Review 3.  Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics.

Authors:  Laurent Castera
Journal:  Liver Int       Date:  2020-02       Impact factor: 5.828

Review 4.  A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient.

Authors:  Adam C Winters; Rasham Mittal; Thomas D Schiano
Journal:  Clin Transplant       Date:  2019-09-08       Impact factor: 2.863

5.  The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter.

Authors:  Maneerat Chayanupatkul; Divya B Dasani; Kristian Sogaard; Thomas D Schiano
Journal:  Transplant Proc       Date:  2020-05-17       Impact factor: 1.066

6.  Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation.

Authors:  C Rigamonti; M F Donato; M Fraquelli; F Agnelli; G Ronchi; G Casazza; G Rossi; M Colombo
Journal:  Gut       Date:  2008-01-24       Impact factor: 23.059

7.  Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations.

Authors:  Laurent Castéra; Juliette Foucher; Pierre-Henri Bernard; Françoise Carvalho; Daniele Allaix; Wassil Merrouche; Patrice Couzigou; Victor de Lédinghen
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

8.  Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.

Authors:  Jeffrey Cui; Elhamy Heba; Carolyn Hernandez; William Haufe; Jonathan Hooker; Michael P Andre; Mark A Valasek; Hamed Aryafar; Claude B Sirlin; Rohit Loomba
Journal:  Hepatology       Date:  2015-12-18       Impact factor: 17.425

Review 9.  Diagnostic accuracy of magnetic resonance elastography in liver transplant recipients: A pooled analysis.

Authors:  Siddharth Singh; Sudhakar K Venkatesh; Andrew Keaveny; Sharon Adam; Frank H Miller; Patrick Asbach; Edmund M Godfrey; Alvin C Silva; Zhen Wang; Mohammad Hassan Murad; Sumeet K Asrani; David J Lomas; Richard L Ehman
Journal:  Ann Hepatol       Date:  2016 May-Jun       Impact factor: 2.400

10.  Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.

Authors:  Mohammad Shadab Siddiqui; Michael O Idowu; Katharine Stromberg; Adam Sima; Emily Lee; Samarth Patel; Sophia Ghaus; Carolyn Driscoll; Richard K Sterling; Binu John; Chandra S Bhati
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-06       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.